IC
LEGN icon

Ikarian Capital’s Legend Biotech LEGN Stock Holding History

Ikarian Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-226,888
Closed -$4.1M – 177
2026
Q1 		$4.1M Hold
226,888
– – 0.33% 67
2025
Q4 		$4.93M Buy
+226,888
New +$6.5M 0.39% 64
2023
Q3 		– Sell
-25,000
Closed -$1.73M – 161
2023
Q2 		$1.73M Buy
+25,000
New +$1.63M 0.27% 71
2020
Q3 		– Sell
-5,000
Closed -$213K – 197
2020
Q2 		$213K Buy
+5,000
New +$195K 0.02% 148

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Ikarian Capital's LEGN Position: Q2 2026 in Review

Ikarian Capital sold out of Legend Biotech (LEGN) in Q2 2026, closing a stake of 226,888 shares — an estimated $4.1M sold.

Ikarian Capital first reported a position in LEGN in Q2 2020 and held it in 4 quarters. The position peaked at $4.93M in Q4 2025. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Ikarian Capital reported no remaining Legend Biotech position as of Q2 2026 after selling out during the quarter.
  • Ikarian Capital sold 226,888 Legend Biotech shares in Q2 2026, an estimated $4.1M.
  • Ikarian Capital first reported a position in Legend Biotech in Q2 2020 and held it in 4 quarters.
  • Ikarian Capital's Legend Biotech position peaked at $4.93M in Q4 2025.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.